DPP4 and chronic myelogenous leukemia, BCR-ABL1 positive: Depending on this, anti-CD26 antibody or anti-IL-1RAP antibody can be modified on the surface of nanoparticles to achieve cell-specific targeting to CML stem cells in future studies.